Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
8 papers
Recent·Most cited
G. Liang, T. G. Oh, N. Hah, H. Tiriac, Y. Shi, M. L. Truitt, C. E. Antal, A. R. Atkins, Y. Li, C. Fraser, S. Ng, A. F. Pinto, D. C. Nelson, S. Bashi, E. Banayo, , R. M. Evans
This study shows that inhibiting stromal Class I HDACs reduces pancreatic cancer progression by targeting desmoplastic and pro-tumorigenic programs in cancer-associated fibroblasts.
Nature Communications · Dec 6, 2023Peer-reviewedCancer Biology
C. Billon, S. Banerjee, S. Situala, R. Welch, L. Hegazy, B. Elgendy, T. G. Oh, M. Kazantzis, A. Chatterjee, J. Chrivia, M. Hayes, W. Xu, A. Hamilton, J. Huss, L. Zhang, , T. Burris
A synthetic ERRα agonist activates an acute aerobic exercise genetic program in skeletal muscle, enhancing exercise capacity and mitochondrial function in mice.
bioRxiv · Oct 5, 2022 · PreprintPharmacology & Toxicology
R. J. Shaw, S. N. Brun, J. Lumibao, A. Limpert, H. Ren, A. Ianniciello, N. Cosford, H. Tiriac, M. Downes, R. Evans, D. D. Engle
This study shows ULK1 is essential for pancreatic cancer cell growth and survival, and ULK1 inhibitors can enhance immunotherapy by increasing MHC Class I expression.
bioRxiv · May 15, 2021 · PreprintCancer Biology
M. Iwamoto, T. Masuya, M. Hosose, K. Tagawa, T. Ishibashi, E. Yoshihara, M. Downes, R. M. Evans, A. Matsushima
This study identifies bisphenol A derivatives as novel coactivator binding inhibitors for estrogen receptor β, showing dual agonist/antagonist activities and a new ligand interaction site.
bioRxiv · May 10, 2021Biochemistry
D. R. Sandoval, T. Mandel Clausen, C. Nora, J. A. Magida, A. P. Cribbs, A. Denardo, A. E. Clark, A. F. Garretson, J. K. C. Coker, A. Narayanan, S. A. Majowicz, M. Philpott, C. Johansson, J. E. Dunford, C. B. Spliid, , Mazitsch
This study identifies halofuginone as a potent inhibitor of SARS-CoV-2 infection and replication by reducing heparan sulfate biosynthesis and suppressing viral replication.
bioRxiv · Mar 22, 2021 · PreprintMicrobiology
N. Casanova Vallve, D. Duglan, M. E. Vaughan, M. K. Handzlik, W. Fan, R. Yu, C. Liddle, M. Downes, J. Delezie, R. Mello, A. B. Chan, M. Pariollaud, P. Westermark, C. Metallo, R. Evans, K. A. Lamia
This study shows that daily running in mice changes their muscle circadian rhythms and improves exercise performance depending on the time of day.
bioRxiv · Oct 19, 2020Physiology
S. Xu, O. Chaudhary, P. Rodriguez-Morales, X. Sun, R. Zappasodi, Z. Xu, A. F. M. Pinto, A. Williams, D. Chen, J. S. Low, Y. Farsakoglu, W. Tang, H. Wang, S. K. Varanasi, B. McDonald, , S. M. Kaech
This study identifies CD36-mediated lipid peroxidation driven by oxidized lipids as a mechanism suppressing anti-tumor CD8 T cell functions in murine tumors.
bioRxiv · Sep 3, 2020Immunology
S. Bapat, Y. Liang, S. Liu, L.-j. Zhang, I. Vogel, D. J. Marr, C. Zhou, E. J. Choi, C. Chang, N. He, M. LeBlanc, I.-k. Lee, J. M. Suh, L. E. Crotty Alexander, C. Liddle, , Y. Zheng
This study shows obesity increases TH2 immunopathology by disrupting PPARγ in T cells, and TZDs can protect against this effect in obese mice.
bioRxiv · Oct 31, 2019 · PreprintImmunology